M R Nelson1, J J McNeil, A Peeters, C M Reid, H Krum. 1. Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Melbourne, VIC. mark.nelson@med.monash.edu.au
Abstract
OBJECTIVES: To determine the extent to which "current guidelines" for the management of hypertension are reflected in the prescribing of antihypertensive drugs in Australia over the period 1994-1998, and to examine the cost implications of actual and recommended prescribing patterns. DESIGN: Federal Government and consumer cost estimates modelled on prescribing patterns and guideline recommendations over the period 1994-1998. SETTING: Prescribing on Federal Government pharmaceutical schemes over the 1994-1998 period. MAIN OUTCOME MEASURES: Estimates of Pharmaceutical Benefits Scheme/Repatriation Pharmaceutical Benefits Scheme cost changes in Australian dollar values. RESULTS: The implementation of current guidelines for patients with uncomplicated hypertension taking monotherapy alone could have reduced drug costs by $45-$108 million in 1998. CONCLUSIONS: Current prescribing patterns indicate that clinical practice has pre-empted the results from clinical trials of newer, more expensive agents and that clinicians' prescribing patterns do not closely reflect current recommendations.
OBJECTIVES: To determine the extent to which "current guidelines" for the management of hypertension are reflected in the prescribing of antihypertensive drugs in Australia over the period 1994-1998, and to examine the cost implications of actual and recommended prescribing patterns. DESIGN: Federal Government and consumer cost estimates modelled on prescribing patterns and guideline recommendations over the period 1994-1998. SETTING: Prescribing on Federal Government pharmaceutical schemes over the 1994-1998 period. MAIN OUTCOME MEASURES: Estimates of Pharmaceutical Benefits Scheme/Repatriation Pharmaceutical Benefits Scheme cost changes in Australian dollar values. RESULTS: The implementation of current guidelines for patients with uncomplicated hypertension taking monotherapy alone could have reduced drug costs by $45-$108 million in 1998. CONCLUSIONS: Current prescribing patterns indicate that clinical practice has pre-empted the results from clinical trials of newer, more expensive agents and that clinicians' prescribing patterns do not closely reflect current recommendations.
Authors: Philip C Skelding; Sumit R Majumdar; Ken Kleinman; Cheryl Warner; Susanne Salem-Schatz; Irina Miroshnik; Lisa Prosser; Steven R Simon Journal: J Clin Hypertens (Greenwich) Date: 2006-06 Impact factor: 3.738
Authors: Margaret Williamson; Magnolia Cardona-Morrell; Jeffrey D Elliott; James F Reeve; Nigel P Stocks; Jon Emery; Judith M Mackson; Jane M Gunn Journal: BMC Health Serv Res Date: 2012-08-23 Impact factor: 2.655